N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 100, Issue , 2016, Pages 94-100

  Higel, Fabian ^a   Seidl, Andreas ^a   Sörgel, Fritz ^b,c   Friess, Wolfgang ^d  

^a Sandoz Biopharmaceuticals   (Germany)

^b IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Fusion protein; Glyco engineering; Monoclonal antibody; N glycosylation; Pharmacokinetics

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; PROTEIN VARIANT; POLYSACCHARIDE;

HUMAN; NONHUMAN; PHARMACOKINETIC PARAMETERS; PROTEIN ENGINEERING; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; ANIMAL; CHEMISTRY; GLYCOSYLATION; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; POLYSACCHARIDES;

EID: 84957991319     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2016.01.005     Document Type: Review

References (89)

1. G. Köhler, and C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495 497
2. J.M. Reichert Marketed therapeutic antibodies compendium MAbs 4 2012 413 415 10.4161/mabs.19931
3. C.A. Abel, H.L. Spiegelberg, and H.M. Grey Carbohydrate content of fragments and polypeptide chains of human. gamma. G-myeloma proteins of different heavy-chain subclasses Biochemistry 7 1968 1271 1278 10.1021/bi00844a004
4. F. Matsuda, K. Ishii, P. Bourvagnet, K.I. Kuma, H. Hayashida, T. Miyata, and et al. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus J. Exp. Med. 188 1998 2151 2162
5. W.E.I. Wang, S. Singh, D.L. Zeng, K. King, S. Nema, and W.E.T. Al Antibody structure, instability, and formulation J. Pharm. Sci. 96 2007 1 26 10.1002/jps
6. Y.D. Liu, A.M. Goetze, R.B. Bass, and G.C. Flynn N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies J. Biol. Chem. 286 2011 11211 11217 10.1074/jbc.M110.185041
7. H. Liu, G. Gaza-Bulseco, D. Faldu, C. Chumsae, and J. Sun Heterogeneity of monoclonal antibodies J. Pharm. Sci. 97 2008 2426 2447 10.1002/jps.21180
8. B. Cai, H. Pan, and G.C. Flynn C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo Biotechnol. Bioeng. 108 2011 404 412 10.1002/bit.22933
9. D. Chelius, D.S. Rehder, and P.V. Bondarenko Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies Anal. Chem. 77 2005 6004 6011 10.1021/ac050672d
10. L.W. Dick, D. Qiu, R.B. Wong, and K.-C. Cheng Isomerization in the CDR2 of a monoclonal antibody: binding analysis and factors that influence the isomerization rate Biotechnol. Bioeng. 105 2010 515 523 10.1002/bit.22561
11. R.J. Harris, B. Kabakoff, F.D. Macchi, F.J. Shen, M. Kwong, J.D. Andya, and et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody J. Chromatogr. B Biomed. Sci. Appl. 752 2001 233 245
12. D.W. Aswad, M.V. Paranandi, and B.T. Schurter Isoaspartate in peptides and proteins: formation, significance, and analysis J. Pharm. Biomed. Anal. 21 2000 1129 1136 10.1016/S0731-7085(99)00230-7
13. H. Liu, G. Gaza-bulseco, and C. Chumsae Glutamine deamidation of a recombinant monoclonal antibody Rapid Commun. Mass Spectrom. 2008 4081 4088 10.1002/rcm
14. R. Bischoff, and H.V.J. Kolbe Deamidation of asparagine and glutamine residues in proteins and peptides: structural determinants and analytical methodology J. Chromatogr. B Biomed. Sci. Appl. 662 1994 261 278 10.1016/0378-4347(94)00203-7
15. A.M. Goetze, Y.D. Liu, T. Arroll, L. Chu, and G.C. Flynn Rates and impact of human antibody glycation in vivo Glycobiology 22 2011 221 234 10.1093/glycob/cwr141
16. J. Yang, R. Primack, M. Frohn, W. Wang, P. Luan, M.W. Retter, and et al. Impact of glycation on antibody clearance AAPS J. 17 2015 237 244 10.1208/s12248-014-9694-4
17. H. Liu, and K. May Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function MAbs 4 2012 17 23 10.4161/mabs.4.1.18347
18. T.M. Dillon, M.S. Ricci, C. Vezina, G.C. Flynn, Y.D. Liu, D.S. Rehder, and et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass - supplementary material J. Biol. Chem. 283 2008 1 15 10.1074/jbc.M709988200
19. A. Guo, M. Han, T. Martinez, R.R. Ketchem, S. Novick, C. Jochheim, and et al. Electrophoretic evidence for the presence of structural isoforms specific for the IgG2 isotype Electrophoresis 29 2008 2550 2556 10.1002/elps.200800083
20. J. Wypych, M. Li, A. Guo, Z. Zhang, T. Martinez, M.J. Allen, and et al. Human IgG2 antibodies display disulfide-mediated structural isoforms J. Biol. Chem. 283 2008 16194 16205 10.1074/jbc.M709987200
21. R. Jefferis Glycosylation as a strategy to improve antibody-based therapeutics Nat. Rev. Drug Discov. 8 2009 226 234 10.1038/nrd2804
22. G.C. Flynn, X. Chen, Y.D. Liu, B. Shah, and Z. Zhang Naturally occurring glycan forms of human immunoglobulins G1 and G2 Mol. Immunol. 47 2010 2074 2082 10.1016/j.molimm.2010.04.006
23. F. Higel, U. Demelbauer, A. Seidl, W. Friess, and F. Sörgel Reversed-phase liquid-chromatographic mass spectrometric N-glycan analysis of biopharmaceuticals Anal. Bioanal. Chem. 405 2013 2481 2493 10.1007/s00216-012-6690-3
24. X. Chen, and G.C. Flynn Analysis of N-glycans from recombinant immunoglobulin G by on-line reversed-phase high-performance liquid chromatography/mass spectrometry Anal. Biochem. 370 2007 147 161 10.1016/j.ab.2007.08.012
25. K. Zheng, C. Bantog, and R. Bayer The impact of glycosylation on monoclonal antibody conformation and stability MAbs 3 2011 568 576 10.4161/mabs.3.6.17922
26. Y. Mimura, S. Church, R. Ghirlando, P.R. Ashton, S. Dong, M. Goodall, and et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms Mol. Immunol. 37 2001 697 706
27. S. Krapp, Y. Mimura, R. Jefferis, R. Huber, and P. Sondermann Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity J. Mol. Biol. 325 2003 979 989 10.1016/S0022-2836(02)01250-0
28. D. Houde, Y. Peng, S.A. Berkowitz, and J.R. Engen Post-translational modifications differentially affect IgG1 conformation and receptor binding Mol. Cell. Proteomics 9 2010 1716 1728 10.1074/mcp.M900540-MCP200
29. A.W. Barb, and J.H. Prestegard NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic Nat. Chem. Biol. 7 2011 147 153 10.1038/nchembio.511
30. S. Radaev, and P. Sun Recognition of immunoglobulins by Fcgamma receptors Mol. Immunol. 38 2002 1073 1083
31. R. Abès, and J.-L. Teillaud Impact of glycosylation on effector functions of therapeutic IgG Pharmaceuticals 3 2010 146 158 10.3390/ph3010146
32. G. Zou, H. Ochiai, W. Huang, Q. Yang, C. Li, and L. Wang Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor J. Am. Chem. Soc. 133 2011 18975 18991 10.1021/ja208390n
33. Y. Mimura, P. Sondermann, R. Ghirlando, J. Lund, S.P. Young, M. Goodall, and et al. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding J. Biol. Chem. 276 2001 45539 45547 10.1074/jbc.M107478200
34. M. Satoh, S. Iida, and K. Shitara Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies Expert Opin. Biol. Ther. 6 2006 1161 1173 10.1517/14712598.6.11.1161
35. T.S. Raju Terminal sugars of Fc glycans influence antibody effector functions of IgGs Curr. Opin. Immunol. 20 2008 471 478 10.1016/j.coi.2008.06.007
36. E.D. Lobo, R.J. Hansen, and J.P. Balthasar Antibody pharmacokinetics and pharmacodynamics J. Pharm. Sci. 93 2004 2645 2668 10.1002/jps.20178
37. D.C. Roopenian, and S. Akilesh FcRn: the neonatal Fc receptor comes of age Nat. Rev. Immunol. 7 2007 715 725 10.1038/nri2155
38. A.G. Morell, G. Gregoriadis, I.H. Scheinberg, J. Hickman, and G. Ashwell The role of sialic acid in determining the survival of glycoproteins in the circulation J. Biol. Chem. 246 1971 1461 1467
39. R.J. Stockert The asialoglycoprotein receptor: relationships between structure, function, and expression Physiol. Rev. 75 1995 591 609
40. G. Ashwell, and J. Harford Carbohydrate-specific receptors of the liver Annu. Rev. Biochem. 51 1982 531 554 10.1146/annurev.bi.51.070182.002531
41. P. Allavena, M. Chieppa, P. Monti, and L. Piemonti From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor Crit. Rev. Immunol. 24 2004 179 192 10.1615/CritRevImmunol.v24.i3.20
42. S.J. Lee, S. Evers, D. Roeder, A.F. Parlow, J. Risteli, L. Risteli, and et al. Mannose receptor-mediated regulation of serum glycoprotein homeostasis Science 295 2002 1898 1901 10.1126/science.1069540
43. P.R. Taylor, S. Gordon, and L. Martinez-Pomares The mannose receptor: linking homeostasis and immunity through sugar recognition Trends Immunol. 26 2005 104 110 10.1016/j.it.2004.12.001
44. X. Chen, Y.D. Liu, and G.C. Flynn The effect of Fc glycan forms on human IgG2 antibody clearance in humans Glycobiology 19 2009 240 249 10.1093/glycob/cwn120
45. A.M. Goetze, Y.D. Liu, Z. Zhang, B. Shah, E. Lee, P.V. Bondarenko, and et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans Glycobiology 21 2011 949 959 10.1093/glycob/cwr027
46. L. Alessandri, D. Ouellette, and A. Acquah Increased serum clearance of oligomannose species present on a human IgG1 molecule MAbs 4 2012 509 520
47. T.A. Millward, M. Heitzmann, K. Bill, U. Längle, P. Schumacher, and K. Forrer Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice Biologicals 36 2008 41 47 10.1016/j.biologicals.2007.05.003
48. M.M. Newkirk, J. Novick, M.M. Stevenson, M.J. Fournier, and P. Apostolakos Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice Clin. Exp. Immunol. 106 1996 259 264
49. Y. Kanda, T. Yamada, K. Mori, A. Okazaki, M. Inoue, K. Kitajima-Miyama, and et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types Glycobiology 17 2007 104 118 10.1093/glycob/cwl057
50. F. Higel, A. Seidl, U. Demelbauer, M. Viertlboeck-Schudy, V. Koppenburg, U. Kronthaler, and et al. N-glycan PK profiling using a high sensitivity nanoLCMS work-flow with heavy stable isotope labeled internal standard and application to a preclinical study of an IgG1 biopharmaceutical Pharm. Res. 2015 10.1007/s11095-015-1724-0
51. M. Yu, D. Brown, C. Reed, S. Chung, and J. Lutman Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans MAbs 1-13 2012
52. L. Liu, A. Stadheim, L. Hamuro, T. Pittman, W. Wang, D. Zha, and et al. Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials Biologicals 39 2011 205 210 10.1016/j.biologicals.2011.06.002
53. L. Huang, S. Biolsi, K.R. Bales, and U. Kuchibhotla Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization Anal. Biochem. 349 2006 197 207 10.1016/j.ab.2005.11.012
54. J. Bongers, J. Devincentis, J. Fu, P. Huang, D.H. Kirkley, K. Leister, and et al. Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography-mass spectrometry peptide mapping J. Chromatogr. A 1218 2011 8140 8149 10.1016/j.chroma.2011.08.089
55. A.J.S. Jones, D.I. Papac, E.H. Chin, R. Keck, S.A. Baughman, Y.S. Lin, and et al. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys Glycobiology 17 2007 529 540 10.1093/glycob/cwm017
56. R. Keck, N. Nayak, L. Lerner, S. Raju, S. Ma, T. Schreitmueller, and et al. Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content Biologicals 36 2008 49 60 10.1016/j.biologicals.2007.05.004
57. H. Kogelberg, B. Tolner, S.K. Sharma, M.W. Lowdell, U. Qureshi, M. Robson, and et al. Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy Glycobiology 17 2007 36 45 10.1093/glycob/cwl053
58. L. Liu, S. Gomathinayagam, L. Hamuro, T. Prueksaritanont, W. Wang, T.A. Stadheim, and et al. The impact of glycosylation on the pharmacokinetics of a TNFR2:Fc fusion protein expressed in glycoengineered Pichia pastoris Pharm. Res. 2012 10.1007/s11095-012-0921-3
59. E. Ezan, and F. Bitsch Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies Bioanalysis 1 2009 1375 1388 10.4155/bio.09.121
60. W. Wang, J. Vlasak, Y. Li, P. Pristatsky, Y. Fang, T. Pittman, and et al. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies Mol. Immunol. 48 2011 860 866 10.1016/j.molimm.2010.12.009
61. H. Li, and M. d'Anjou Pharmacological significance of glycosylation in therapeutic proteins Curr. Opin. Biotechnol. 20 2009 678 684 10.1016/j.copbio.2009.10.009
62. L. Huang, J. Lu, V.J. Wroblewski, J.M. Beals, and R.M. Riggin In vivo deamidation characterization of monoclonal antibody by LC/MS/MS Anal. Chem. 77 2005 1432 1439 10.1021/ac0494174
63. K.R. Anumula New HPLC assay for glycosyltransferases based on derivatization with anthranilic acid and fluorescence detection Glycobiology 22 2012 912 917 10.1093/glycob/cws067
64. M. Melmer, T. Stangler, M. Schiefermeier, W. Brunner, H. Toll, A. Rupprechter, and et al. HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals Anal. Bioanal. Chem. 2010 905 914 10.1007/s00216-010-3988-x
65. M. Melmer, T. Stangler, A. Premstaller, and W. Lindner Comparison of hydrophilic-interaction, reversed-phase and porous graphitic carbon chromatography for glycan analysis J. Chromatogr. A 1218 2011 118 123 10.1016/j.chroma.2010.10.122
66. B.D. Prater, H.M. Connelly, Q. Qin, and S.L. Cockrill High-throughput immunoglobulin G N-glycan characterization using rapid resolution reverse-phase chromatography tandem mass spectrometry Anal. Biochem. 385 2009 69 79 10.1016/j.ab.2008.10.023
67. L.R. Ruhaak, C. Huhn, W.-J. Waterreus, A.R. de Boer, C. Neusüss, C.H. Hokke, and et al. Hydrophilic interaction chromatography-based high-throughput sample preparation method for N-glycan analysis from total human plasma glycoproteins Anal. Chem. 80 2008 6119 6126 10.1021/ac800630x
68. K.R. Anumula, and S.T. Dhume High resolution and high sensitivity methods for oligosaccharide mapping and characterization by normal phase high performance liquid chromatography following derivatization with highly fluorescent anthranilic acid Glycobiology 8 1998 685 694
69. F. Higel, A. Seidl, U. Demelbauer, F. Sörgel, and W. Frieß Small scale affinity purification and high sensitivity reversed phase nanoLC-MS N-glycan characterization of mAbs and fusion proteins MAbs 6 2014 894 903 10.4161/mabs.29263
70. L.A. Gennaro, J. Delaney, P. Vouros, D.J. Harvey, and B. Domon Capillary electrophoresis/electrospray ion trap mass spectrometry for the analysis of negatively charged derivatized and underivatized glycans Rapid Commun. Mass Spectrom. 16 2002 192 200 10.1002/rcm.564
71. R. Haselberg, V. Brinks, A. Hawe, G.J. de Jong, and G.W. Somsen Capillary electrophoresis-mass spectrometry using noncovalently coated capillaries for the analysis of biopharmaceuticals Anal. Bioanal. Chem. 400 2011 295 303 10.1007/s00216-011-4738-4
72. M. Nakano, D. Higo, E. Arai, T. Nakagawa, K. Kakehi, N. Taniguchi, and et al. Capillary electrophoresis-electrospray ionization mass spectrometry for rapid and sensitive N-glycan analysis of glycoproteins as 9-fluorenylmethyl derivatives Glycobiology 19 2009 135 143 10.1093/glycob/cwn115
73. L.A. Gennaro, and O. Salas-Solano On-line CE-LIF-MS technology for the direct characterization of N-linked glycans from therapeutic antibodies Anal. Chem. 80 2008 3838 3845 10.1021/ac800152h
74. L.A. Gennaro, D.J. Harvey, and P. Vouros Reversed-phase ion-pairing liquid chromatography/ion trap mass spectrometry for the analysis of negatively charged, derivatized glycans Rapid Commun. Mass Spectrom. 17 2003 1528 1534 10.1002/rcm.1079
75. I. Ritamo, J. Räbinä, S. Natunen, and L. Valmu Nanoscale reversed-phase liquid chromatography-mass spectrometry of permethylated N-glycans Anal. Bioanal. Chem. 405 2013 2469 2480 10.1007/s00216-012-6680-5
76. M. Wuhrer, C.A.M. Koeleman, A.M. Deelder, and C.H. Hokke Normal-phase nanoscale liquid chromatography-mass spectrometry of underivatized oligosaccharides at low-femtomole sensitivity Anal. Chem. 76 2004 833 838 10.1021/ac034936c
77. H. Kalay, M. Ambrosini, P.H.C. van Berkel, P.W.H.I. Parren, Y. van Kooyk, and J.J. García Vallejo Online nanoliquid chromatography-mass spectrometry and nanofluorescence detection for high-resolution quantitative N-glycan analysis Anal. Biochem. 423 2012 153 162 10.1016/j.ab.2012.01.015
78. A. Beck, E. Wagner-Rousset, M. Bussat, M. Lokteff, C. Klinguer-Hamour, J. Haeuw, and et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins Curr. Pharm. Biotechnol. 9 2008 482 501
79. C. Zupke, L.J. Brady, P.G. Slade, P. Clark, R.G. Caspary, B. Livingston, and et al. Real-time product attribute control to manufacture antibodies with defined N-linked glycan levels Biotechnol. Prog. 31 2015 1433 1441 10.1002/btpr.2136
80. C.D. Rillahan, A. Antonopoulos, C.T. Lefort, R. Sonon, P. Azadi, K. Ley, and et al. Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome Nat. Chem. Biol. 8 2012 661 668 10.1038/nchembio.999
81. K.M. Cox, J.D. Sterling, J.T. Regan, J.R. Gasdaska, K.K. Frantz, C.G. Peele, and et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor Nat. Biotechnol. 24 2006 1591 1597 10.1038/nbt1260
82. A. Beck, O. Cochet, and T. Wurch GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins Expert Opin. Drug Discov. 5 2010 95 111 10.1517/17460440903413504
83. N. Yamane-Ohnuki, S. Kinoshita, M. Inoue-Urakubo, M. Kusunoki, S. Iida, R. Nakano, and et al. Establishment ofFUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity Biotechnol. Bioeng. 87 2004 614 622 10.1002/bit.20151
84. Y. Kanda, H. Imai-Nishiya, R. Kuni-Kamochi, K. Mori, M. Inoue, K. Kitajima-Miyama, and et al. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics J. Biotechnol. 130 2007 300 310 10.1016/j.jbiotec.2007.04.025
85. C. Ferrara, P. Brünker, T. Suter, S. Moser, U. Püntener, and P. Umaña Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous β1, 4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II Biotechnol. Bioeng. 93 2006 851 861 10.1002/bit.20777
86. T. Shinkawa, K. Nakamura, N. Yamane, E. Shoji-Hosaka, Y. Kanda, M. Sakurada, and et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity J. Biol. Chem. 278 2003 3466 3473 10.1074/jbc.M210665200
87. E. Mössner, P. Brünker, S. Moser, U. Püntener, C. Schmidt, S. Herter, and et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell - mediated B-cell cytotoxicity Blood 115 2010 4393 4402 10.1182/blood-2009-06-225979
88. C.A. Gerdes, V.G. Nicolini, S. Herter, E. Van Puijenbroek, S. Lang, M. Roemmele, and et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab Clin. Cancer Res. 19 2013 1126 1138 10.1158/1078-0432.CCR-12-0989
89. A. Ito, T. Ishida, H. Yano, A. Inagaki, S. Suzuki, F. Sato, and et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2R??null mouse model Cancer Immunol. Immunother. 58 2009 1195 1206 10.1007/s00262-008-0632-0